Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Yarrow Bioscience, Inc.MNLO · Entity 6871 | See Remarks | December 11, 2019 | December 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Yarrow Bioscience, Inc.
Report date December 11, 2019 · Filed December 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 15,819 |
Ending reported balance
After 2019-12-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-12-11 · Exercise / conversion · Acquired 24,090 · Balance 24,090 F1: On July 29, 2019, the Reporting Person was granted 24,090 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. Row 2 · 2019-12-11 · Tax withholding · Disposed 8,271 · Balance 15,819 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-12-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-11 · Exercise / conversion · Disposed 24,090 · Balance 0 F1: On July 29, 2019, the Reporting Person was granted 24,090 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 29, 2019, the Reporting Person was granted 24,090 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2019 Filed Dec 14, 2019 02:58 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionRestricted Stock Units · Derivative | 24,090 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029191 · doc4.xml · derivative · entry 3 Krasnow Ronald A. · CIK 0001591469 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,090 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 29, 2019, the Reporting Person was granted 24,090 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. F1 · derivative.exercise_date: On July 29, 2019, the Reporting Person was granted 24,090 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. F1 · derivative.expiration_date: On July 29, 2019, the Reporting Person was granted 24,090 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. Read SEC document |
| December 11, 2019 Filed Dec 14, 2019 02:58 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon stock | 8,271 | $4.52 | $37,384.92 |
DisclosureSEC source: 0000899243-19-029191 · doc4.xml · nonDerivative · entry 2 Krasnow Ronald A. · CIK 0001591469 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,819 Read SEC document |
| December 11, 2019 Filed Dec 14, 2019 02:58 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionCommon stock | 24,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-029191 · doc4.xml · nonDerivative · entry 1 Krasnow Ronald A. · CIK 0001591469 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 29, 2019, the Reporting Person was granted 24,090 restricted stock units ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:37 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantRestricted Stock Units · Derivative | 24,090 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-020706 · doc4.xml · derivative · entry 1 Krasnow Ronald A. · CIK 0001591469 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,090 Underlying: Common Stock · 24,090 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs shall vest in two (2) equal annual installments beginning July 29, 2020, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F3 · derivative.expiration_date: Not Applicable Read SEC document |
| June 17, 2019 Filed Jun 27, 2019 20:17 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 130,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0000899243-19-018360 · doc4.xml · derivative · entry 1 Krasnow Ronald A. · CIK 0001591469 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2029-06-17 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.